Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064777 | 0.91 | HTR6 (0.71) | HTR6ELANE | |
| SCHEMBL2064982 | 0.88 | HTR6 (0.57) | HTR6ELANE | |
| SCHEMBL7484905 | 0.83 | HTR6 (0.83) | HTR6 | |
| SCHEMBL2064502 | 0.78 | HTR6 (0.71) | HTR6 | |
| SCHEMBL7488906 | 0.78 | HTR6 (0.55) | HTR6 | |
| SCHEMBL7489435 | 0.76 | HTR6 (0.61) | HTR6 | |
| SCHEMBL4674250 | 0.76 | HTR6 (0.77) | HTR6 | |
| SCHEMBL7482946 | 0.74 | HTR6 (0.59) | HTR6 | |
| SCHEMBL7490243 | 0.74 | HTR6 (0.56) | HTR6 | |
| SCHEMBL7486314 | 0.74 | HTR6 (1.00) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148394-B2 | Azaindoles having serotonin receptor affinity | NPS PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-07-08 | — | — | US | claimed |
| EP-1204662-B1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP (CA) | 2004-06-02 | — | — | EP | claimed |
| EP-1204662-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS Allelix Corp. (CA) | 2002-05-15 | — | — | EP | claimed |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | ALLELIX BIOPHARMACEUTICALS, INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001012629-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP. (US) | 2001-02-22 | — | — | WO | claimed |
| US-20120302596-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8148394-B2 | Azaindoles having serotonin receptor affinity | NPS PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20080004307-A1 | Azaindoles Having Serotonin Receptor Affinity | NPS ALLELIX CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7268127-B2 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP (CA) | 2007-09-11 | — | — | US | disclosed |
| US-20050239788-A1 | Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor | NPS ALLELIX CORP. (CA) | 2005-10-27 | — | — | US | disclosed |
| US-6916818-B2 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2005-07-12 | — | — | US | disclosed |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| EP-1204662-B1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP (CA) | 2004-06-02 | — | — | EP | disclosed |
| US-6686374-B1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-02-03 | — | — | US | disclosed |
| EP-1204662-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS Allelix Corp. (CA) | 2002-05-15 | — | — | EP | disclosed |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | ALLELIX BIOPHARMACEUTICALS, INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001012629-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6191141-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEN DISORDERS | NPS ALLELIX CORP. (CA) | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302596-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | HTR6, DRD2, HTR1A | HTR6 1/4885ELANE 3679/4885 |
| US-20080004307-A1 | Azaindoles Having Serotonin Receptor Affinity | HTR6, DRD2, HTR1A | HTR6 1/4885ELANE 3679/4885 |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | DRD2, HTR3C, HTR2C | HTR6 8/4885ELANE 3752/4885 |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | DRD2, DRD3, HTR3C | HTR6 14/4885ELANE 2615/4885 |
| US-20050239788-A1 | Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor | CRHR1, HTR6, HTR1A | HTR6 2/4885ELANE 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.